Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$250 Mln
Revenue (TTM)
$145 Mln
Net Profit (TTM)
$-345 Mln
ROE
-15.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
18.3
Industry P/E
--
EV/EBITDA
-1.5
Div. Yield
0 %
Debt to Equity
-1.7
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
161,024,000
CFO
$-696.98 Mln
EBITDA
$-473.44 Mln
Net Profit
$-924.07 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
LumiraDx (LMDX)
| -74.6 | 81.8 | -62.4 | -96.7 | -88.2 | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
LumiraDx (LMDX)
| -93.0 | -89.9 |
|
BSE Sensex
| 18.7 | 4.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic... platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom. Read more
Co-Founder, Chairman & CEO
Mr. Ron Zwanziger
Co-Founder, Chairman & CEO
Mr. Ron Zwanziger
Headquarters
London
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of LumiraDx Ltd (LMDX) is $0.02 (NASDAQ) as of 04-Apr-2024 16:00 EDT. LumiraDx Ltd (LMDX) has given a return of -88.17% in the last 3 years.
Since, TTM earnings of LumiraDx Ltd (LMDX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
The 52-week high and low of LumiraDx Ltd (LMDX) are Rs -- and Rs -- as of 03-Apr-2026.
LumiraDx Ltd (LMDX) has a market capitalisation of $ 250 Mln as on 04-Apr-2024. As per SEBI classification, it is a company.
Before investing in LumiraDx Ltd (LMDX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.